Drug intelligence / Profile preview

agubecimig

Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

Agubecimig (RG6209, RO7497372) is an investigational bispecific antibody fragment (DutaFab) developed by Genentech and Roche for the treatment of retinal diseases, including diabetic macular edema (DME). It is designed to simultaneously target and inhibit vascular endothelial growth factor A (VEGF-A) and interleukin-6 (IL-6), thereby addressing both angiogenesis and inflammation associated with retinal vascular disorders. Agubecimig is currently in Phase I clinical development (e.g., the PREGONDA study, NCT06847854) where it is administered via intravitreal injection.

Other names: VEGF x IL-6 DutaFabVEGF-IL-6 DutaFabVEGF-IL6 DutaFabVEGF-IL 6 DutaFab

Targets

IL-6 (Interleukin 6)IL-6R (Interleukin-6 receptor subunit alpha)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on agubecimig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on agubecimig.

Work on agubecimig? Claim this page to correct or add information. Claim this page